Caris Life Sciences (United States)
CAI
$26.27
+6.88%
Caris Life Sciences, Inc. is a next-generation AI TechBio company that develops and commercializes precision medicine solutions, leveraging comprehensive molecular profiling and artificial intelligence/machine learning algorithms to transform healthcare. As a relatively new public entity (listed June 2025), it operates in the biotechnology industry with a focus on enabling personalized treatment decisions through its advanced diagnostic and data platforms. The current investor narrative centers on the company's rapid revenue growth and recent surge in stock price, driven by strong adoption of its molecular intelligence offerings and a positive earnings trajectory, though the stock remains volatile and down significantly from its 52-week high, prompting debate about its valuation and long-term profitability.…
CAI
Caris Life Sciences (United States)
$26.27
Investment Opinion: Should I buy CAI Today?
Rating: Buy. The thesis is that Caris Life Sciences is a high-growth precision medicine leader with accelerating revenue and improving margins, but valuation is rich. Analyst consensus is Buy with an average target of $27.00, implying modest upside. Supporting evidence includes 78.8% YoY revenue growth, positive EBITDA of $17.2M, gross margin of 65.4%, and a forward PE of 69.5x. The PS ratio of 9.38x is a premium to the sector, but the PEG ratio of 0.48 suggests growth is undervalued. Risks include valuation compression if growth slows, competition, and regulatory changes. This Buy would downgrade to Hold if revenue growth falls below 50% or PS ratio exceeds 12x, and upgrade to Strong Buy if the stock pulls back to $20 while fundamentals remain strong. Overall, the stock is fairly valued relative to its growth potential, but investors should be prepared for volatility.
Sign up to view all
CAI 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The company's rapid revenue growth and improving profitability are strong indicators, but the high valuation and earnings volatility warrant caution. The stock is likely to outperform if growth continues, but a slowdown could lead to significant downside. Key factors to monitor are quarterly revenue growth, margin trends, and analyst revisions. An upgrade to high confidence would require sustained profitability and revenue growth above 60%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Caris Life Sciences (United States)'s 12-month outlook, with a consensus price target around $27.00 and implied upside of +2.8% versus the current price.
Average Target
$27.00
0 analysts
Implied Upside
+2.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$22 - $36
Analyst target range
The target price range spans from $22.00 (low) to $36.00 (high), representing a wide spread of 64% from low to high, indicating significant uncertainty about the company's future performance. The high target of $36.00 implies a 37% upside and likely assumes continued rapid revenue growth and margin expansion, while the low target of $22.00 suggests a 16% downside, possibly reflecting concerns about competition or profitability. Recent institutional ratings have been consistently positive, with firms like Evercore ISI, BTIG, and JP Morgan maintaining Buy/Outperform ratings, but the wide range highlights the speculative nature of the stock.
Bulls vs Bears: CAI Investment Factors
Caris Life Sciences presents a compelling growth story with accelerating revenue and improving profitability, but the stock trades at a significant premium to peers, reflecting high expectations. The bull case is supported by strong analyst sentiment and recent momentum, while the bear case highlights valuation risk and earnings volatility. Currently, the bull side has stronger evidence given the rapid growth and positive trajectory, but the key tension is whether the company can sustain its growth rate and achieve consistent profitability to justify its premium valuation. If growth decelerates or margins fail to expand, the stock could face significant downside.
Bullish
- Revenue Growth Accelerating Sharply: Q1 2026 revenue surged 78.8% YoY to $216.2M, following a 35% YoY increase in Q4 2025 ($292.9M). This acceleration indicates strong market adoption of its molecular profiling services and a scalable business model.
- Improving Profitability Trajectory: The company achieved positive EBITDA of $17.2M in Q1 2026 (8% margin), a dramatic turnaround from negative EBITDA in prior quarters. Operating margin turned positive at 2.4%, signaling operational leverage as revenue scales.
- Strong Analyst Consensus and Upside: With a Buy rating from 12 analysts and an average target of $27.00, the stock has 2.8% upside from $26.27. The high target of $36.00 implies 37% upside, reflecting confidence in continued growth.
- Robust Balance Sheet and Liquidity: Current ratio of 7.85 and debt-to-equity of 0.66 indicate strong liquidity and manageable leverage. This financial flexibility supports R&D investment and potential strategic initiatives.
Bearish
- Elevated Valuation Premium: PS ratio of 9.38x is over 100% above the biotech sector average of 3-5x. Forward PE of 69.5x implies high growth expectations, leaving little room for disappointment.
- Inconsistent Earnings History: Trailing twelve-month EPS is -$0.07, with a net margin of -66.2%. While Q4 2025 showed a profit, Q1 2026 returned to a slight loss, indicating volatile profitability.
- Significant Drawdown Risk: The stock is 31.1% below its 52-week high of $42.50 and has experienced a max drawdown of -62.98%. This volatility suggests high risk for investors.
- Wide Analyst Target Range: Target prices range from $22.00 to $36.00, a 64% spread, indicating high uncertainty about future performance. The low target implies 16% downside from current levels.
CAI Technical Analysis
The stock is in a strong recovery phase, having surged 70.8% over the past month and 68.9% over the past three months, yet it remains 31.1% below its 52-week high of $42.50. Currently trading at $26.27, the price sits at 61.8% of its 52-week range (between $14.19 and $42.50), indicating a rebound from the lows but still well off the peak. This positioning suggests renewed bullish momentum, though the stock has not fully recovered from its earlier decline, which saw a maximum drawdown of -62.98%.
Beta
—
—
Max Drawdown
-63.0%
Largest decline past year
52-Week Range
$14-$40
Price range past year
Annual Return
-31.1%
Cumulative gain past year
| Period | CAI Return | S&P 500 |
|---|---|---|
| 1m | +70.8% | +3.6% |
| 3m | +68.9% | +2.7% |
| 6m | +34.5% | +11.4% |
| 1y | -31.1% | +18.7% |
| ytd | -2.6% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAI Fundamental Analysis
Revenue growth is accelerating sharply, with the most recent quarter (Q1 2026) reporting revenue of $216.2 million, up 78.8% year-over-year. This follows a trend of sequential improvement: Q4 2025 revenue was $292.9 million (up from $216.8 million in Q3 2025), though Q1 2026 saw a seasonal dip. The growth is driven by the company's core molecular profiling services, with a notable contribution from pharma R&D services of $5.4 million in Q1. The rapid expansion suggests strong market adoption and a scalable business model, though the sustainability of this growth rate remains a key question.
Quarterly Revenue
$216174000.0B
2026-03
Revenue YoY Growth
+78.8%
YoY Comparison
Gross Margin
65.4%
Latest Quarter
Free Cash Flow
$123456000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAI Overvalued?
Given that the trailing twelve-month net income is negative (EPS of -$0.07), the price-to-sales (PS) ratio is the most appropriate valuation metric, standing at 9.38x. The forward PE of 69.5x implies the market expects significant earnings growth, but the negative trailing earnings make PE less meaningful. The PS ratio is elevated compared to the broader biotech sector, which typically trades at 3-5x sales, indicating a premium of over 100%. This premium reflects the company's high growth and AI-driven differentiation, but it also prices in substantial future profitability.
PE
-14.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 2x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
632.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's negative trailing EPS of -$0.07 and net margin of -66.2%, indicating ongoing profitability challenges. While Q4 2025 showed a profit, Q1 2026 returned to a slight loss, highlighting earnings volatility. The debt-to-equity ratio of 0.66 is manageable, but the high PS ratio of 9.38x means the stock is priced for perfection, leaving little room for error. Cash flow is positive (FCF TTM of $123.5M), but the company's reliance on continued growth to justify valuation is a key risk.
FAQ
The key risks are: 1) Valuation risk - the stock trades at a high PS ratio of 9.38x, leaving little room for error; 2) Earnings volatility - the company has a negative trailing EPS of -$0.07 and inconsistent profitability; 3) Competitive risk - the precision medicine market is competitive, and new entrants could pressure growth; 4) Macro risk - as a high-beta stock, it is sensitive to market sentiment and interest rates. The most severe risk is a growth deceleration, which could lead to a 30%+ drop from current levels.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $30-$36, driven by sustained high growth and margin expansion; Base case (50% probability) targets $24-$30, with growth moderating but remaining strong; Bear case (20% probability) targets $18-$22, if growth disappoints. The most likely scenario is the base case, with the stock trading around the analyst average target of $27.00. Key assumptions include revenue growth of 50-60% and gradual margin improvement.
CAI is trading at a PS ratio of 9.38x, which is over 100% above the biotech sector average of 3-5x, indicating a premium valuation. However, the PEG ratio of 0.48 suggests that the growth rate justifies the premium. The forward PE of 69.5x implies the market expects significant earnings growth. Compared to its own history, the stock is below its 52-week high of $42.50, so it is not at peak valuation. Overall, the stock is fairly valued relative to its growth potential, but it is not cheap.
CAI is a good buy for investors with a high risk tolerance who believe in the long-term growth of precision medicine. The stock has strong revenue growth (78.8% YoY) and positive analyst sentiment (Buy rating, average target $27.00), but it is volatile and trades at a premium valuation (PS 9.38x). The biggest downside risk is a growth slowdown, which could lead to a 16% drop to the low target of $22.00. For those who can stomach volatility, the risk/reward is attractive, but it is not suitable for conservative investors.
CAI is more suitable for long-term investment (3-5 years) given its high growth stage and volatility. The stock has a beta that is likely high, and its short-term price movements are unpredictable. For long-term investors, the company's growth potential in precision medicine and AI could yield significant returns. For short-term traders, the recent momentum (70.8% monthly gain) offers opportunities, but the risk of sharp pullbacks is high. A minimum holding period of 3 years is recommended to ride out volatility and allow the growth story to unfold.